José Diaz

发表

Elicitation of health state utilities in soft tissue sarcoma

A. Lloyd, P. Swinburn, C. Benson, 2013, Quality of Life Research.

First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials

H. Pandha, S. Takyar, José Diaz, 2016, Anti-cancer drugs.

Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma

T. Delea, R. Motzer, C. Sternberg, 2016, Oncology.

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries

C. Porta, M. Neary, J. Bellmunt, 2014, Cancer medicine.

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom

T. Delea, Arati Sharma, D. Chandiwana, 2017, PloS one.

Quality‐adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma

R. Motzer, T. Powles, J. Beaumont, 2016, Cancer.

Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC)

D. Rea, J. Kleijnen, M. Amonkar, 2012, Current medical research and opinion.

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

C. Porta, T. Powles, D. Cella, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments

M. Neary, G. Demetri, M. Duh, 2015, BMC Cancer.

Validation of a short questionnaire to measure symptoms and functional limitations associated with hand‐foot syndrome and mucositis in patients with metastatic renal cell carcinoma

J. Beaumont, D. Cella, J. Lai, 2016, Cancer.

Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.

T. Delea, José Diaz, J. Amdahl, 2015, Journal of managed care & specialty pharmacy.

Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom

T. Delea, A. Chit, L. Lewis, 2014, Sarcoma.

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

C. Porta, M. Neary, W. Oh, 2013, International journal of oncology.

Validation of the supplementary quality of life questionnaire for mouth/throat and hand/foot soreness.

J. Beaumont, D. Cella, José Diaz, 2013 .

Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study.

R. Motzer, Chun-Ming Huang, K. Deen, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PCN70 Cost Effectiveness Analysis Based on Progression Free Survival (PFS) of Pazopanib Versus Sunitinib for the Treatment of Advanced Renal Cell Carcinoma (ARCC) in the Mexican Context

T. Delea, P. Anaya, José Diaz, 2012 .

Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN).

T. Powles, R. Motzer, J. Beaumont, 2014 .

Quality of Life (QOL) among Renal Cell Carcinoma (RCC) Patients in A Randomized Double Blind Cross-Over Patient Preference Study of Pazopanib (P) Versus Sunitinib (S)

S. Lata, C. Porta, J. Beaumont, 2012 .